Fig. 1 · Structure

Documents & Downloads

Tubacin

Cat. No. A10954 CAS 537049-40-4

HDAC6 inhibitor

Tubacin (tubulin acetylation inducer) is a highly potent and selective, reversible, cell-permeable HDAC6 inhibitor with an IC50 of 4 nM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
HDAC6 (Cell-free assay) 4 nM

Cellular Effect

Cell Line Activity Value Description Reference
A549 EC50 2.5 μM Inhibition of HDAC-6 in human A549 cells assessed as induction of alpha-tubulin acetylation after 20 hrs by cytoblot analysis 10.1039/C1MD00199J
A549 EC50 2.9 μM Inhibition of HDAC6 in human A549 cells assessed as induction of alpha-tubulin acetylation by fluorescence microscopy [PMID: 16408003]
HeLa IC50 2.9 μM Inhibition of HDAC6 in human HeLa cells assessed as reduction in K40 hyperacetylation of alpha-tubulin incubated for 6 hrs by immunofluorescence assay [PMID: 25454270]
HeLa IC50 2.9 μM Inhibition of HDAC6 in human HeLa cells using acetyl tubulin as substrate assessed as Ac-Lys accumulation in nuclear histones after 6 hrs by immunofluorescence assay [PMID: 23964961]

In Vitro Studies

Tubacin yielded an IC50 of 1.52 μM for intracellular infectious virus titers in JEV-infected human cerebellar medulloblastoma TE671 cells compared with untreated infected cells. In T24 cells, Tubacin produced a dose-dependent decrease in viability. In unloaded chondrocytes without IL-1β, Tubacin increased acetylated α-tubulin expression. Tubacin pretreatment yielded an IC50 of 1.89 μM for SRIP-driven EGFP reporter fluorescence in TE671 cell monolayers compared with untreated infected cells. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Tubacin effects on intracellular infectious virus titers

Cell-based study · Human cerebellar medulloblastoma TE671 cells [1]

Human cerebellar medulloblastoma TE671 cells infected with JEV were treated with Tubacin for 36 h. Compared with untreated infected cells, Tubacin had an IC50 of 1.52 μM for intracellular infectious virus titers.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
intracellular infectious virus titersIC50 1.52 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 1, 5, and 10 μM
Exposure duration
36 h treatment
Co-treatment
Other interventions in this design: JEV. Compound effect isolated by the comparison: infected cells treated with or without tubacin.
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Tubacin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. Antiviral Activity of Pan- and Selective-HDAC Inhibitors Against JEV (S10); 4. Methods and Materials > 4.1. Cells and Virus (S40); 4. Methods and Materials > 4.4. Quantitative Assays of Virus Yield and Intracellular Viral Titer (S60); Figure 3 legend (S102, S104, S105)

intracellular infectious virus titers: intracellular infectious virus titers; comparator: untreated infected cells — 2. Results > 2.1. Antiviral Activity of Pan- and Selective-HDAC Inhibitors Against JEV (S10)

Tubacin effects on cell viability

Cell-based study · T24 cells [2]

In T24 cells, Tubacin treatment at micromolar concentrations produced a dose-dependent decrease in cell viability at 24 h and 72 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
viability of T24 cellsReported result a dose-dependent decrease in cell viability at 24 h and 72 h[2]

Literature-Reported Treatment Conditions

Treatment concentration
micromolar concentrations
Exposure duration
24 h and 72 h
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Tubacin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Reagents (S5); Materials and methods > Cell viability assay (S8); Results > The selective HDAC6i tubacin radiosensitizes human bladder cancer cells (S98, S99); Fig. 3 legend (S173, S180)

viability of T24 cells: viability of T24 cells; comparator: control — Results > The selective HDAC6i tubacin radiosensitizes human bladder cancer cells (S99); Fig. 3 legend (S173)

Tubacin effects on acetylated α-tubulin expression

Cell-based study · chondrocytes [3]

In unloaded cells, in the absence of IL-1β, treatment with tubacin (0.5 μM) for 24 h increased expression of acetylated α-tubulin.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
expression of acetylated α-tubulinReported result In unloaded cells, in the absence of IL-1β, treatment with tubacin (0.5 μM) for 24 h increased expression of acetylated α-tubulin [P = 0.006, Fig. 6(D)].[3]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 μM
Exposure duration
24 h
Reported limits
Not stated in the sentences used: route, vehicle, control.
Methods and source locations

Compound reported in the paper: Tubacin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Inhibition of HDAC6 restores cilia elongation and blocks the anti-inflammatory effects of mechanical loading in the presence of IL-1β (S119); Results > In unloaded cells, pharmaceutical inhibition of IL-1β mediated tubulin acetylation suppresses inflammatory signalling and cilia elongation (S136)

expression of acetylated α-tubulin: expression of acetylated α-tubulin — Results > In unloaded cells, pharmaceutical inhibition of IL-1β mediated tubulin acetylation suppresses inflammatory signalling and cilia elongation (S136)

Tubacin effects on reporter fluorescence in a pretreatment assay

Cell-based study · TE671 cells monolayer [1]

TE671 cell monolayers were pretreated with Tubacin for 1 h before JEV SRIP infection. Compared with untreated infected cells, Tubacin had an IC50 of 1.89 μM for green fluorescence intensity of the SRIP-driven EGFP reporter.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
green fluorescence intensity of SRIP-driven EGFP reporterIC50 1.89 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 1, 5, and 10 μM
Exposure duration
pretreated with tubacin (0, 1, 5, and 10 μM) for 1 h; 36 h post infection
Co-treatment
Other interventions in this design: JEV SRIPs 10 TCID50. Compound effect isolated by the comparison: compared with untreated infected cells.
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Tubacin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.2. Preventive and Therapeutic Activities of Tubacin against JEV Infection (S20); 4. Methods and Materials > 4.6. Time-of-Addition Assay (S73, S74); Figure 5 legend (S114); Figure 7 legend (S121)

green fluorescence intensity of SRIP-driven EGFP reporter: green fluorescence intensity of SRIP-driven EGFP reporter; comparator: untreated infected cells — 2. Results > 2.2. Preventive and Therapeutic Activities of Tubacin against JEV Infection (S20)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 537049-40-4
Applications HDAC6 inhibitor
Formula C41H43N3O7S
Molecular Weight 721.9
SMILES
C1[C@@H](O[C@@H](O[C@@H]1C2=CC=C(C=C2)CO)C3=CC=C(C=C3)NC(=O)CCCCCCC(=O)NO)CSC4=NC(=C(O4)C5=CC=CC=C5)C6=CC=CC=C6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 93 mg/mL (128.83 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Lu CY, Chang YC, Hua CH, et al. Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis. Int J Mol Sci (2017). PMID: 28468311 DOI: 10.3390/ijms18050954 Source material
  2. [2] Tsai YC, Wang TY, Hsu CL, et al. Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling. Br J Cancer (2023). PMID: 36810912 DOI: 10.1038/s41416-023-02195-0 Source material
  3. [3] Fu S, Thompson CL, Ali A, et al. Mechanical loading inhibits cartilage inflammatory signalling via an HDAC6 and IFT-dependent mechanism regulating primary cilia elongation. Osteoarthritis Cartilage (2019). PMID: 30922983 DOI: 10.1016/j.joca.2019.03.003 Source material

Added to your cart

View Cart Checkout
Loading...